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Epstein–Barr Virus (EBV) Isolated 
from EBV-Related Malignancies
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Abstract
Epstein–Barr virus (EBV) is the cause of certain cancers, such as Burkitt 
lymphoma, Hodgkin lymphoma, NK/T cell lymphoma, nasopharyngeal carci-
noma, and a subset of gastric carcinomas. The genome-wide characteristics of 
EBV are essential to understand the diversity of strains isolated from EBV-related 
malignancies, provide the first opportunity to test the general validity of the EBV 
genetic map and explore recombination, geographic variation, and the major 
features of variation in this virus. Moreover, understanding more about EBV 
sequence variations isolated from EBV-related malignancies might give important 
implications for the development of effective prophylactic and therapeutic vaccine 
approaches targeting the personalized or geographic-specific EBV antigens in these 
aggressive diseases. In this chapter, we will mainly focus on the EBV genome-wide 
profiling in three common EBV-related cancers in Asia, including nasopharyngeal 
carcinoma, EBV-associated gastric carcinoma, and NK/T-cell lymphoma.
Keywords: Epstein–Barr virus (EBV), next-generation sequencing (NGS), 
nasopharyngeal carcinoma (NPC), EBV-associated gastric carcinoma (EBVaGC), 
NK/T-cell lymphoma (NKTCL)
1. Introduction
Epstein–Barr virus (EBV), a ubiquitous human herpesvirus discovered in 
1964 is classified as a group I carcinogen by the International Agency for Research 
on Cancer (IARC), since the latent infection by EBV has been estimated to be 
responsible for 200,000 cancer cases worldwide [1], including Burkitt lymphoma, 
Hodgkin lymphoma, NK/T cell lymphoma (NKTCL), nasopharyngeal carcinoma 
(NPC), and a subset of gastric carcinomas. It has been shown that viruses can 
contribute to the biology of multistep oncogenesis and are implicated in many of 
the hallmarks of cancer [2]. Notably, the discovery of links between viral infection 
and cancer types has provided actionable opportunities, such as the use of human 
papilloma virus (HPV) vaccines as a preventive measure, to reduce the global 
impact of cancer. However, until now, approved vaccines for EBV have not been 
available.
EBV has a double stranded DNA genome comprised of approximately 172 
kilobases. The expression products cover at least 86 proteins and 46 functional 
small-untranslated RNAs [3–5]. EBV has two distinct life cycles: latency and lytic 
Epstein-Barr Virus
2
replication. During latency, viral genomes only express a limited number of latent 
proteins (EBV-determined nuclear antigen 1 (EBNA1), 2, 3A, 3B, and 3C and EBNA 
leader protein (EBNA-LP); latent membrane protein 1 (LMP1) and LMP2 (which 
encodes two isoforms, LMP2A and LMP2B)), noncoding EBV-encoded RNAs 
(EBER1 and EBER2), and viral miRNAs (BHRF1-miRNA and BART-miRNA). EBV 
latency is categorized as three latency types (latency I–III). EBV genomes in type-I 
latency are known to express EBNA1 and EBER. EBV genomes in type-II latency 
are known to express more genes such as EBNA-LP, LMP1, LMP2A, and LMP2B. 
EBV genomes in type-III latency are known to express most restricted latent genes 
including EBNA2, EBNA3A, EBNA3B, and EBNA3C. Lytic genes encode viral tran-
scription factors (e.g., BZLF1), a viral DNA polymerase (BALF5) and associated 
factors, and viral glycoproteins (e.g., gp350/220 and gp110) and structural proteins 
(capsid and tegument proteins).
Southern blot of restriction fragment length polymorphisms was first used to 
detect EBV strain variation, and Sanger sequencing of certain specific viral genes 
(e.g., EBNA1 and LMP1) was later developed to detect sequence diversity. Now, 
on the basis of high-throughput sequencing, genome-wide analysis is becoming 
possible.
Prior to 2013, EBV whole genome sequences available from GenBank were 
limited to less than 10 strains (B95-8, EBV-WT, GD1, AG876, GD2, HKNPC1, Akata, 
and Mutu). The prototypic type 1 EBV strain B95-8 was the first complete genome 
sequenced from an individual with infectious mononucleosis using a conventional 
strategy (i.e., subcloning followed by Sanger sequencing) [6]. Subsequently, a 
more representative type 1 EBV reference genome, human herpesvirus 4 complete 
wild type genome, was constructed by using B95-8 as the backbone with an 11-kb 
deletion segment provided by the Raji sequences (named EBV-WT) [7]. AG876 was 
the unique complete type 2 EBV sequence from a Ghanaian case of Burkitt lym-
phoma [8]. Akata and Mutu were sequenced from Burkitt lymphoma cell lines from 
a Japanese patient and a Kenyan patient, respectively [9]. GD1 [10], GD2 [11] and 
HKNPC1 [12] were isolated from NPC patients.
Since 2014, a new technology named Hybrid Capture (Figure 1), has marked a 
new era of EBV genome sequencing. Using the method of target enrichment of EBV 
DNA by hybridization, followed by next-generation sequencing, de novo assembly, 
and joining of contigs can yield complete EBV genomes. The development of high-
throughput sequencing technologies enabled sequencing of EBV genomes derived 
from a wide variety of clinical samples, such as tumor biopsy samples [13]. The 
number of available EBV sequences is increasing exponentially and up to now, more 
than 500 EBV genomes have been sequenced from a variety of human malignancies, 
including NPC, lymphoma, gastric cancer, and lung cancer, as well as from healthy 
carriers [14–25]. Progress has made it possible that the population-based case–control 
studies of EBV strain variation in EBV-related cancer patients as compared with the 
healthy population and a comprehensive survey of EBV integration in a variety of 
human malignancies can be effectively conducted [20, 25–27]. These developments 
have revealed that various EBV strains are differentially distributed throughout the 
world, and that the behavior of cancer-derived EBV strains is different from that of 
the prototype EBV strain of noncancerous origin.
Hence, the genome-wide characteristics of EBV are essential to assess the diversity 
of strains isolated from EBV-related malignancies. Meanwhile, understanding the 
pattern of EBV sequence variation is important for knowing whether there is a disease-
related strain-specific or geographic regional variation of EBV strain, and might 
provide important implications for the development of effective prophylactic and 
therapeutic vaccine approaches targeting the personalized or geographic-specific EBV 
antigens in these aggressive diseases.
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In this chapter, EBV genomes reviewed are from three common EBV-related 
cancers in Asia, including NPC, EBV-associated gastric carcinoma (EBVaGC), 
and NKTCL. The EBV strains include GD1 [10], GD2 [11], HKNPC1 [12], 
Figure 1. 
Complete workflow for EBV DNA capture and sequencing.
EBV strain Origin Disease Year Refs
GD1 Guangdong, China NPC 2005 [10]
GD2 Guangdong, China NPC 2011 [11]
HKNPC1 Hong Kong, China NPC 2012 [12]
HKNPC2-HKNPC9 Hong Kong, China NPC 2014 [14]
EBVaGC1-EBVaGC9 Beijing, China EBVaGC 2016 [17]
GDGC1-GDGC2 Guangdong, China EBVaGC 2018 [21]
NKTCL-EBV1-NKTCL-EBV8 Beijing, China NKTCL 2019 [23]
NKTCL-SC01-NKTCL-SC15 15 from Southern China,  
12 from Singapore
NKTCL 2019 [24]
NKTCL-SG01-NKTCL-SG12
Table 1. 
EBV genomes reviewed in this chapter
Epstein-Barr Virus
4
HKNPC2-HKNPC9 [14], EBVaGC1-EBVaGC9 [17], GDGC1-GDGC2 [21], NKTCL- 
EBV1-NKTCL-EBV8 [23], NKTCL-SC01-NKTCL-SC15 and NKTCL-SG01-
NKTCL-SG12 [24] (Table 1).
2. Genomic diversity of EBV-related malignances
2.1 NPC
NPC, an EBV-associated epithelial carcinoma, has a unique geographical 
distribution [28]. A recent World Health Organization (WHO) report estimated 
that there were around 130,000 new NPC cases worldwide in 2018 [29]. Rare in 
most of the world, NPC is particularly prevalent in South China and Southeast 
Asia [30]. In Hong Kong and Guangdong in South China, NPC incidence is as high 
as 12.8–25.0/100,000 per year [28, 29]. The cause of NPC endemicity remains 
unknown.
Many studies have shown that EBV genome is present in almost all endemic NPC 
tumors with a unique pattern of virus latent gene expression, suggesting that EBV 
plays an important role in the tumorigenesis of NPC [31]. Whole genome sequencing 
is useful for us to understand genomic characterization and divergence. Here, we 
mainly focus on 11 mostly available full-length genomes of NPC.
2.1.1 GD1
GD1 (Guangdong strain 1), the first NPC-derived EBV strain with full-length 
sequences determined using PCR amplification and sub-cloning followed by con-
ventional Sanger sequencing technology, was analyzed from established a lympho-
blastoid cell line (LCL) from umbilical cord blood mononuclear cells transformed 
by saliva virus from a Cantonese NPC patient in 2005 [10]. The entire GD1 sequence 
is 171,656 bp in length and GD1 belongs to type 1 strain. Many sequence variations 
in GD1 compared to prototypical strain B95-8 were detected, including 43 deletion 
sites, 44 insertion sites, and 1413 point mutations. Furthermore, the frequency of 
some GD1 mutations in Cantonese NPC patients was evaluated, such as a 30-bp 
deletion in the C terminus of LMP1, and the V-Val subtypes of EBNA1. The results 
suggested that GD1 is highly representative of the EBV strains isolated from NPC 
patients in Guangdong, China, an area with the highest incidence of NPC in the 
world.
2.1.2 GD2
With the invention of next-generation sequencing (NGS) systems, it is possible 
to determine genome-wide sequences and the viral clonality of EBV strains by 
direct sequencing of EBV genomes in clinical tumors in a time- and cost-effective 
manner. GD2 with 164,701 bp long was directly sequenced using the Illumina 
(Solexa) platform, and successfully assembled from an NPC tumor of a patient in 
Guangdong province, a region in China by the same group who determined GD1 
[11]. GD2 was closely related to GD1 by sequence and phylogenetic analyses. The 
sequence similarities between GD2 and GD1 were 98.76%. GD2 and GD1 shared 505 
common single-nucleotide variations (SNVs), including most SNVs in the coding 
regions (348 [68.91%] SNVs) and seven insertion and deletions (indels). From 
a comparison with the EBV-WT reference genome, a total of 927 SNVs and 160 
indels with genome-wide distribution were found in the GD2 genome. The results 
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revealed that NGS allows the characterization of genome-wide variations of EBV in 
clinical tumors and provides evidence of monoclonal expansion of EBV in vivo.
2.1.3 HKNPC1
Because of the relatively small quantity of viral DNA present in the tumor sample, 
next-generation sequencing total cellular and viral DNA in a sample is costly and 
inefficient, and may limit the generation of the high read depth necessary to make 
high confident base calls of the viral genome. Using target enrichment technology 
could increase the relative amount of viral DNA. Kwok et al. reported an approach 
of PCR enrichment (Amplicon Sequencing) followed by sequencing the amplified 
products on the Illumina Genome Analyzer IIx platform to determine the genome 
sequence of an EBV isolate from NPC tumor of a Chinese patient in Hong Kong, 
designated as HKNPC1 [12]. HKNPC1 is approximately 171,549 bp, and contains 
1589 SNVs and 132 indels in comparison to the reference EBV-WT sequence. Non-
synonymous SNVs were mainly found in the latent, tegument and glycoprotein 
genes. The same point mutations were found in glycoprotein (BLLF1 and BALF4) 
genes of GD1, GD2 and HKNPC1 strains and might affect cell type specific binding. 
The results showed that whole genome sequencing of EBV in NPC may facilitate 
discovery of previously unknown variations of pathogenic significance.
2.1.4 HKNPC2-9
The group of Kwok and colleagues established a complete sequencing workflow 
comprising target enrichment of EBV DNA by hybridization, followed by next-
generation sequencing, de novo assembly, and joining of contigs by Sanger sequencing 
to yield whole EBV genomes. The sequences of eight NPC biopsy specimen-derived 
EBV (NPC-EBV) genomes, designated HKNPC2 to HKNPC9, were then determined 
in the same geographic location in order to reveal their sequence diversity [14]. The 
eight NPC-EBV genome sizes estimated based on the reference EBV-WT sequence 
ranged from 170,062 bp (HKNPC2) to 171,556 bp (HKNPC3 and -6). A total of 1736 
variations were found, including 1601 substitutions, 64 insertions, and 71 deletions, 
compared to the reference EBV-WT genome. Furthermore, genes encoding latent, 
early lytic, and tegument proteins and glycoproteins were found to contain nonsyn-
onymous mutations of potential biological significance. Thus, much greater sequence 
diversity among EBV isolates derived from NPC biopsy specimens is demonstrated on 
a whole-genome level through a complete sequencing workflow.
Obtaining whole-genome sequence information for more clinical EBV isolates, 
with good representation of the EBV repertoire in tumors, could help to address that 
hypothesis and uncover the pathogenic subtypes of EBV in NPC tumorigenesis. A 
case–control (62 NPC patients and 142 population carriers) study of NPC in Hong 
Kong has identified high-risk EBV subtypes with polymorphisms in the EBV-
encoded small RNA (EBER) locus [26]. A recent study published in Nature Genetics 
entitled ‘Genome sequencing analysis identifies high-risk Epstein–Barr virus sub-
types for nasopharyngeal carcinoma’ by Xu et al. used large-scale EBV whole-genome 
sequencing to examine EBV subtypes in an attempt to explain the unique NPC 
endemicity in South China [25]. Through EBV genomes from 156 NPC cases and 
47 controls and two-stage association study, they identified two non-synonymous 
EBV variants within the BALF2 gene (BamHIA leftward reading frame 2 encoding a 
single strand DNA binding protein associated with EBV replication) strongly asso-
ciated with the risk of NPC (odds ratio [OR] = 8.69 for SNP162476_C and OR = 6.14 
for SNP163364_T). The cumulative effects of these variants contribute to 83% of 
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the overall risk of NPC in southern China. These studies confirmed the critical role 
of EBV infection in the pathogenesis of NPC and provided an explanation for the 
striking epidemiological distribution of this tumor in South China.
2.2 EBVaGC
EBVaGC has been recognized as a distinct subset of gastric carcinoma, accounting 
for about 10% of total gastric carcinomas [32–35]. The monoclonal presence of the 
virus was uniformly distributed in malignant cells of EBV-positive tumors but not 
observed in the surrounding normal epithelial cells, providing strong evidence to 
support the role of EBV as an etiologic agent [32, 33]. However, the exact role of 
EBV in the development and progression of this specific type of gastric carcinoma is 
not yet clear.
Progress has been made in understanding the full spectrum of diversity existent 
within the EBV genome from EBVaGC clinical tumor samples, since the NGS 
technology has been developed. Here, 11 EBV strains from primary EBVaGC biopsy 
samples were included.
2.2.1 EBVaGC1-EBVaGC9
Our group reported the first genome-wide view of sequence variation of 
EBV isolated from primary EBVaGC biopsy specimens in 2016 [17]. We used 
the method of target enrichment of EBV DNA by hybridization, followed by 
next-generation sequencing. EBV probes were designed according to full-length 
genome of six available EBV strains, including EBV-WT, B95-8, AG876, GD1, GD2, 
and HKNPC1. According to the value of coverage of the target region, all DNA 
sequence generated from GC-EBV strains most resembled GD1. Thus, GD1 was 
used as the reference EBV genome in our study. De novo assembly was performed 
for nine sequenced GC-EBV strains. Finally, nine EBVaGC genomes were success-
fully sequenced, designated EBVaGC1 to EBVaGC9. The genome sizes, estimated 
based on the reference GD1 sequence, ranged from 171,612 bp (EBVaGC6) to 
171,957 bp (EBVaGC1).
Whole-genome sequencing of EBV enabled the comparison and thus the 
determination of EBV variations at the genome level. In our study, 961 variations 
were observed in the EBVaGC1 to 9 genomes in comparison to the reference GD1, 
including 919 substitutions, 23 insertions, and 19 deletions. Both latent genes and 
genes encoding tegument proteins in nine GC-EBV genomes were found to harbor 
the majority of nonsynonymous mutations, accounting for 58.4% (EBVaGC8) to 
84.3% (EBVaGC3) of all nonsynonymous mutations detected for each genome.
EBNA1 is essential for maintenance of the EBV episome in latently infected 
cells and is the only EBV antigen that is consistently expressed in all EBV associ-
ated malignancies [36]. Based on the amino acid changes at position 487 in the 
COOH-terminal region in EBNA1 relative to B95-8 (P-ala), V-val was the most 
common subtype, accounting for 77.7% of nine GC-EBV strains, followed by 
P-thrV, accounting for 22.3%. Multiple results showed that V-val is the dominant 
subtype in Asian regions studies, not only in EBVaGC but also in NPC and healthy 
donors, while V-val subtype was rarely found in Africa, Europe, and America 
irrespective of source (lymphoma, NPC, EBVaGC, or healthy donors) [37–39], 
indicating that polymorphism of EBNA1 subtypes has geographic differences but is 
not tumor-specific. Apart from changes in the C-terminus, EBNA1 has variations 
in the N-terminus. Interestingly, we identified two interstrain recombinants at the 
EBNA1 locus, which provided a further mechanism for the generation of diversity. 
EBNA1 N-terminus changes have revealed additional variants that were not simply 
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classified based on the signature amino acid residue 487 in the C-terminus as 
widely used previously. The N-terminus changes reinforce the need to evaluate the 
EBV genome more comprehensively in order to characterize the full extent of EBV 
genetic diversity. A comprehensive investigation into the functional and immuno-
logical impact of the naturally occurred EBNA1 sequence variations and interstrain 
recombinants is required to evaluate their possible significance, which may also be 
helpful for clarifying the association of EBNA1 subtypes and EBVaGC.
2.2.2 GDGC1 and GDGC2
In 2018, NGS was employed to determine the EBV genomes from two EBVaGC 
specimens, designated as GDGC1 and GDGC2, from Guangdong, China, an 
endemic area of NPC [21]. Due to the presence of the much more abundant cellular 
genomic DNA in the DNA preparations, the number of reads belonging to EBV was 
low, accounting for only 0.02–0.23% of the total reads. However, since the origi-
nal data were sufficient, the average sequencing depth for genomes GDGC1 and 
GDGC2 was ~73x and ~24x, respectively, which was sufficient for further analysis. 
The genome sizes, estimated based on the reference EBV-WT genome sequence, 
were as follows: GDGC1 (169,611 bp) and GDGC2 (171,299 bp).
The authors reported that a total of 1815 SNPs (146 indels) and 1519 SNPs 
(106 indels) were found in GDGC1 and GDGC2, respectively, compared with the 
reference EBV-WT genome. Among these, 1229 SNPs (66 indels) and 1076 SNPs (54 
indels) were located in the coding regions for GDGC1 and GDGC2, respectively, 
while the remaining variations were found in the non-coding regions. Consistent 
with previous reports [17], there is clear evidence for a higher frequency of SNPs 
in latent genes, followed by the genes encoding tegument and membrane glyco-
proteins. In contrast to the frequent mutations that occurred in latent genes, the 
sequences of promoters and ncRNAs were investigated to be strictly conserved. 
A few point mutations were found in the sequences of Cp, Qp, Fp and LMP2Ap, 
and only scattered mutations could be identified in certain ncRNA sequences. 
Promoters and EBV-generated ncRNAs play important roles in regulating viral 
processes and in mediating host-virus interactions. Thus, a detailed EBV genome-
wide analysis of EBVaGC from Guangdong was performed, which would be helpful 
for further understanding of the relationship between EBV genomic variation and 
EBVaGC carcinogenesis.
The features of the disease and geographically associated EBV genetic variation 
as well as the roles that the variation plays in carcinogenesis and evolution remain 
unclear. A recent study sequenced 95 geographically distinct EBV isolates from 
EBVaGC biopsies (n = 41) and saliva of healthy donors (n = 54) to detect variants 
and genes associated with gastric carcinoma from a genome-wide spectrum [20]. 
BRLF1, BBRF3, and BBLF2/BBLF3 genes had significant associations with gastric 
carcinoma. LMP1 and BNLF2a genes were strongly geographically associated genes 
in EBV. The results provided insights into the genetic basis of oncogenic EBV for 
gastric carcinoma, and the genetic variants associated with gastric carcinoma could 
serve as biomarkers for oncogenic EBV.
2.3 NKTCL
Extranodal NKTCL, a rare type of non-Hodgkin lymphoma, is characterized by 
the presence of EBV in virtually all cases, irrespective of their ethnicity or geo-
graphical origin. NKTCL is an aggressive malignancy, predominantly occurs in the 
nasal, paranasal, and oropharyngeal sites, and is much more prevalent in East Asia 
and Latin America than in Western countries [40].
Epstein-Barr Virus
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Although the association of this B lymphotropic virus with malignancies of 
T and NK cell origin was quite unexpected, both the presence of virus sequences 
in tumor cells and the virus’s oncogenic potency have led to the hypothesis that 
whether particular EBV strains are preferentially selected in NKTCL. Pathogenesis 
and genotype analyses of NKTCL have mainly focused on genetic variations in 
a small fraction of EBV genes before, which is limited to define the spectrum of 
diversity within the whole genome of EBV. The genome-wide characteristics of EBV 
are essential to understand the diversity of strains isolated from NKTCL. In 2019, 
for the first time, 35 NKTCL-derived EBV genomic landscapes at genome-wide 
level were simultaneously systematically characterized by two groups.
2.3.1 NKTCL-EBV1-NKTCL-EBV8
Our group directly sequenced EBV-captured DNA from eight primary NKTCL 
biopsy samples from China using Illumina HiSeq 2500 sequencer platform and 
presented the eight EBV sequences, designated NKTCL-EBV1-NKTCL-EBV8 
[23]. Aiming at knowing the detail of subtype, the obtained DNA sequences were 
compared with six mostly referenced sequences, including AG876, B95-8, EBV WT, 
GD1, GD2, and HKNPC1. The GD1 coverage percentages are higher than the rest. 
The genome sizes, estimated based on the reference GD1 sequence, ranged from 
171,590 bp (NKTCL-EBV8) to 172,059 bp (NKTCL-EBV1).
Whole-genome sequence alignments revealed extensive nucleotide variation in 
the eight NKTCL-EBV genomes. In comparison with the most similar GD1 strain, 
the NKTCL-EBV1 to NKTCL-EBV8 harbored 2072 variations in total, including 
1938 substitutions, 58 insertions, and 76 deletions. Among them, 1218 substitu-
tions, 15 insertions, and 26 deletions were located in the coding regions. The 
number of the nonsynonymous mutations is highest in the gene regions encoding 
latent proteins in each of the NKTCL-EBV genomes, followed by genes encoding 
the tegument protein and membrane glycoproteins.
EBNA1 and LMP1 are the most frequently studied regions to date. Based on the 
amino acid changes in certain residues of LMP1 and EBNA1, eight NKTCL-EBVs 
were sorted to China 1 and V-val subtype, respectively. Of interest, EBNA1 of 
NKTCL-EBV3 sequence showed clustered away from the other seven NKTCL-
EBV strains. Analysis of amino acid sequences of EBNA1 supported that EBNA1 
of NKTCL-EBV3 may arise from recombination of GD1 and B95-8. Other two 
commonly classification systems for LMP-1 gene polymorphisms include a 30-bp 
deletion in the C terminus and the loss of restriction site Xho I in the N terminus 
of the gene. LMP1 is a key latent protein with abilities to promote cell proliferation 
and inhibit cell apoptosis in NKTCL. In our study, the LMP1 strain in NKTCL-
EBV1-NKTCL-EBV7, but not NKTCL-EBV8, harbored the 30-bp deletion. The 
variant of 30-bp deletion of LMP1 has been demonstrated that it is associated with 
poor prognosis of patients with NKTCL, which might serve as a potential marker to 
monitor treatment [41]. In addition, eight NKTCL-EBV strains had Xho I restric-
tion site loss at exon 1 of the LMP1 gene.
2.3.2 NKTCL-SC01-NKTCL-SC15 and NKTCL-SG01-NKTCL-SG12
The other group assembled 27 NKTCL-derived EBV genome sequences retrieved 
from whole-genome sequencing data using the Hiseq sequencer (Illumina), including 
15 EBV-positive NKTCL tumor samples from Southern China and 12 samples from 
Singapore [24]. The average percentage of EBV sequences in WGS data is 0.45% 
(0.03–1.06%), and the coverage depth is 222.2X in average (26.7X–612.8X). As 
~34 kb of 172 kb of EBV genome are repeat regions, which could not be properly 
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assembled with short-reads sequencing technology, the groups assigned “N” for 
these regions and subsequently joined the scaffolds, resulting in EBV genomes with 
~172 kb in length.
The authors reported that among the 27 NKTCL samples, in average 1152 EBV 
SNVs for each sample were determined by aligning the viral reads against the 
reference EBV-WT genome. The most frequent tumor-specific non-synonymous 
mutations in NKTCL-derived EBV were located at BPLF1 gene (position 
49,790–59,239 bp). An average of 44.8 small indels (<50 bp) of EBV were found 
in each NKTCL sample, and the 30-bp deletion of LMP1 was commonly found in 
the samples (21/27), with a frequency consistent with the previous study revealed 
by using Sanger sequencing [42]. Large deletions of EBV (>1 kb) were found in 10 
of 27 NKTCL samples, without any sequencing coverage in the deleted regions. 
The findings provided insights into the understanding of EBV’s role the etiology 
of NKTCL.
A genome-wide association study of 189 patients with extranodal NKTCL, 
nasal type and 957 controls from Guangdong province, Southern China was 
performed to identify common genetic variants affecting individual risk of 
NKTCL [43]. All cases were genotyped with Illumina Human OmniExpress 
ZhongHua-8 BeadChip, and population controls were scanned by Illumina 
OmniHumanExpress-24 V1.0 (both Illumina, San Diego, CA, USA). The findings 
were validated in four independent case–control series. The SNP with the strongest 
association was rs9277378 (OR 2.65 [95% CI 2.08–3.37]) located with HLA-DPB1, 
indicating the importance of HLA-DP antigen presentation in the pathogenesis 
of NKTCL. The pathogenic subtypes of EBV in NKTCL tumorigenesis should be 
further explored.
3. Phylogenetic analysis of the EBV genomes
Phylogenetic analysis of EBV genomes could demonstrate detailed overall 
genomic differences in EBV genome within or beyond subtypes of EBV-associated 
diseases, thus, EBV genomic similarity is likely to better infer the phylogenetic 
relatedness among EBV genomes.
Traditionally, EBV has two distinct subtypes, type 1 and type 2. Type 1 EBV 
(e.g., B95-8, GD1 and Akata) is the main EBV strain prevalent worldwide, while 
type 2 EBV (e.g., AG876) is abundant only in parts of Africa and New Guinea. 
Type 1 and type 2 EBV encode different EBNA2 genes, with only 54% amino acid 
sequence identity. A recent whole genome sequencing study confirmed that EBNA2 
and EBNA3 are the only genes that can distinguish type 1 and type 2 EBV strains 
[16]. Technologies for genome sequencing were currently developed with tools for 
genome analysis. High-throughput sequencing technology such as illumine dye 
sequencing was introduced to successfully sequence viral genomes. As exemplary 
tools for genome analysis, Molecular Evolutionary Genetics Analysis (MEGA) is 
used for both conducting statistical analysis of molecular evolution and construct-
ing phylogenetic trees [44].
The NPC genomes from Asian EBV strains, including GD1, GD2, and HKNPC1-
HKNPC9, are type 1 viruses and were clustered in a branch distant to the non-
Asian strains AG876, B95-8 [14]. Analysis of LMP1 and -2 showed a phylogenetic 
relationship corresponding to the geographical origin of the viral genomes instead 
of the type 1 and 2 dichotomy, indicating that LMP1 and -2 genes can serve as geo-
graphical markers. GD1 seemed to harbor many mutations that were not present 
in the other Chinese strains. HKNPC6 and -7 genomes, which were isolated from 
tumor biopsy specimens of advanced metastatic NPC cases, were distinct from the 
Epstein-Barr Virus
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Figure 2. 
Phylogenetic trees of EBV genomes. Phylogenetic analyses were conducted using the neighbor-joining (NJ) 
algorithm implemented in MEGA software (version 6). Bootstrap analysis of 1000 replicates was performed to 
determine the confidence.
other NPC-EBV genomes. Future work should investigate the relationship between 
the distinct lineage of EBV and the clinical stages of NPC.
GC-EBV strains, EBVaGC1-EBVaGC9 and GDGC1-GDGC2 involved here, were 
closely related to all Asian-derived EBV strains, distant to the non-Asian strains, and 
also showed that the EBV sequences generally clustered in a manner consistent with 
geographical location [17, 21]. Neighbor-joining trees derived from the sequences of 
EBNA2 gene showed that all the GC-EBV genomes are type 1 viruses, clustered in a 
branch with other type 1 EBV strains, distant to the only type 2 EBV strain, AG876. 
Phylogenetic trees based on the LMP1 gene and whole EBV genomes indicated 
that the nine EBVaGC strains were closely related to all Asian-derived EBV strains 
and distant to the non-Asian strains, suggesting that the LMP1 gene can serve as a 
geographical marker [17]. This is in line with the previous results from the NPC-EBV 
genomes [14]. In addition, phylogenetic analyses on GDGC1 and GDGC2 derived 
from specific EBV-encoded gene suggested the presence of at least two parental 
lineages of EBV, as GDGC1 and GD2 clustered closely, while GDGC2 and GD1 
clustered closely [21].
In our recent study, the phylogenetic trees were conducted based on alignment 
of eight full-length NKTCL-EBVs and previously published 28 strains [23]. Of 
note, eight NKTCL-EBVs genomes clearly sort into type 1, based on differences in 
whole genome and especially EBNA2. Eight NKTCL-EBVs were related to other 
Asian EBV strains, including EBVaGC1–9, HKNPC1–9, GD1, and GD2 obtained 
from China, and Akata from Japan, whereas none of the specimens was clustered 
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in a branch of non-Asian strains AG876, B95-8, and Mutu. Other group compared 
the sequences between 27 NKTCL-derived EBV and 164 EBV genome sequences 
from public database to determine the sequence diversity of EBV [24]. Phylogenetic 
analysis revealed clear clustering of EBV isolates firstly according to their respective 
geographic origin; moreover, EBV isolates derived from NKTCL samples tend to 
cluster closely, apart from clusters by other diseases, supporting the hypothesis of 
the existence of disease-specific EBV. However, whether the unique EBV has been 
driving the development of NKTCL or simply adapted to the niche of NKTCL as 
bystander await further investigations.
In this chapter, phylogenetic analysis was conducted on full-length EBV 
genomes, including 11 NPC-EBV strains (GD1, GD2, HKNPC1-HKNPC9), 11 
GC-EBV strains (EBVaGC1-EBVaGC9, GDGC1-GDGC2), 35 NKTCL-EBV strains 
(NKTCL-EBV1-NKTCL-EBV8, NKTCL-SC01-NKTCL-SC15, NKTCL-SG01-
NKTCL-SG12), B95-8, EBV-WT, Mutu, Akata, and AG876 (Figure 2). The result 
of phylogenetic tree supports the conclusion that EBV infections are more likely 
affected by different geographic regions rather than particular EBV-associated 
malignancies.
4. Amino acid changes in CD4+ and CD8+ T-cell epitopes
Sequence variations of EBV genes also result in amino acid epitope exchanges, 
which should have a significant impact on EBV-specific T-cell immunity.
Among the shared non-synonymous SNVs of the Chinese derived GD1, GD2 
and HKNPC1 isolates, 34 are associated with known EBV-specific epitopes; 19 and 
15 are found in CD8+ and CD4+ epitopes, respectively [12]. HKNPC2-9 genomes 
harbored nonsynonymous mutations in epitopes specific for both CD4+ and CD8+ 
T cells [14]. Amino acid changes were found in seven CD8+ epitopes of LMP2, five 
epitopes of EBNA3A, and three or fewer in other proteins. Thirteen CD4+ epitopes 
of EBNA1, six in LMP1, six in LMP2, five in EBNA2, and three or fewer in other 
proteins contained amino acid changes. Some of the nonsynonymous mutations 
were affecting multiple epitopes.
EBVaGC shows EBV type I latency neoplasm, in which EBNA1 is expressed in 
100% and LMP2A in about half of EBVaGC cases, respectively [45]. Recent stud-
ies show that EBNA1, as well as LMP2A, can be presented to both CD4+ and CD8+ 
T cells, highlighting its potential importance in the development of therapeutic 
strategies against EBV-associated malignancies [46, 47]. There is some clear evi-
dence for sequence variation affecting immune recognition of EBNA1 and potential 
epitope selection for vaccine development [46]. So far, most research on the EBNA1 
protein has been focused exclusively on the B95-8 strain alone [46, 47]. Sequence 
analysis of the gene encoding EBNA1 in EBV isolates from nine EBVaGC specimens 
has revealed considerable EBNA1 sequence divergence from the B95-8 strain [17]. 
Importantly, T cell recognition of EBNA1 epitope might be greatly influenced by 
this sequence polymorphism as adoptive transfer of EBNA1-targeted T cells has a 
potential use in immunotherapy of EBV associated carcinomas.
NKTCL is associated with type II EBV latency, in which only restricted 
EBV antigens, namely EBNA1, and LMP1 and 2, are expressed [48]. These EBV 
encoded proteins might be the targets of immune recognition during its persistent 
infection, and their nonsynonymous variations in CD4+ and CD8+ T-cell epit-
opes may affect the efficacy for a cytotoxic T lymphocyte (CTL)-based therapy. 
Many epitopes were defined and were mapped in EBV antigens and correlated 
with major histocompatibility complex type in previous studies. In our study, we 
mainly investigated the amino acid changes in CD4+ and CD8+ T-cell epitopes of 
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EBNA1, LMP1, and LMP2A. Compared with B95-8, amino acids changes were 
found in 3 CD8+ epitopes of EBNA1, 8 epitopes of LMP1, and 12 epitopes of 
LMP2A. Eleven CD4+ epitopes of EBNA1, 13 in LMP1, and 9 in LMP2A contained 
amino acids. Some of the nonsynonymous mutations were affecting multiple 
epitopes [23]. In another study, alterations of the known T-cell epitopes were 
examined in EBV sequences derived from NKTCL [24]. Alterations of T-cell 
epitopes were detected in EBV derived from NKTCL samples. Notably, 21 of 
these epitopes with significant enrichment in NKTCL samples were restricted to 
six EBV genes, including EBNA3A (G373D, F325L, I333K, L406P, S412R, H464R, 
M466R, T585I, and A588P), EBNA3B (A399S, V400L, V417L, K424T, Y662D, and 
K663E), EBNA3C (P916S), BARF1 (V29A), BCRF1 (V6M), and BNRF1 (G456R, 
S497G, and A1289T).
Therefore, these data have implications for the development of effective prophy-
lactic and therapeutic vaccine approaches targeting the personalized EBV antigens 
in these aggressive diseases. Adoptive transfer of cytotoxic T cells (CTLs) specific 
for EBV antigens has proved safe and effective as prophylaxis and treatment for 
EBV-associated lymphoproliferative disease. Some patients with advanced stage 
or relapsed EBV-associated malignancies achieved complete remission after treat-
ment with autologous LMP1/2- and EBNA1-specific CTLs or activated by peptides 
derived from LMP1/2 [49, 50]. Nonetheless, some cases still did not respond to 
LMP-CTL therapy, and this failure was usually attributed to immune escapes by 
antigen loss. It is worth noting that all these previous studies used prototype EBV 
sequence, B95-8, to design full-length LMP epitopes. Therefore, recent work gives 
an alternative explanation for the lack of tumor response. Whether changes in such 
epitopes confer immune evasion of the tumor cells may constitute another hypoth-
esis for future testing.
5. Genomic integration of viral sequences
Viral integration into the host genome has been shown to be a causal mechanism 
that can lead to the development of cancer [51]. Not surprisingly, known tumor-
associated viruses, such as EBV, HBV, HPV16 and HPV18, were among the most 
frequently detected targets [52]. Notably, the approach of WGS is sensitive to detect 
viruses. This is particularly true for the common integration verified for HBV, 
HPV16 and HPV18 in a variety of studies [53–55]. The known causal role of HPV16 
and HPV18 in several tumor entities, which triggered one of the largest measures in 
cancer prevention, has been the motivation for extensive elucidation of the patho-
genetic processes involved. Integration events with high confidence were demon-
strated for HBV (liver cancer), HPV16 and HPV18 (in both cervical and head-and 
neck carcinoma), however, low-confidence integration events were detected for 
EBV (gastric cancer and malignant lymphoma) [56].
Comprehensive analyses of WGS datasets may reveal some novel findings 
on EBV integration. Recently, a comprehensive survey of EBV integration in 
a variety of human malignancies, including NPC, EBVaGC, and NKTCL was 
conducted, using EBV genome capture combined with ultra-deep sequencing, 
which could efficiently detect integrated EBV sequences from background 
“noise” introduced by nuclear EBV episomes [27]. The EBV integration rates 
were 25.6% (10/39), 16.0% (4/25), 9.6% (17/177) in the EBVaGC, NKTCL, and 
NPC tumors, respectively, which were lower than HPV integration in cervi-
cal cancer (76.3%) and head and neck squamous cell carcinoma (60.7%), and 
HBV in hepatocellular carcinoma (92.6%) [54, 57–59]. They found that EBV 
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integrations into the introns could decrease the expression of the inflammation-
related genes, TNFAIP3, PARK2, and CDK15, in NPC tumors [27]. The EBV 
integration breakpoints were frequently at oriP or terminal repeats, and were 
surrounded by microhomology sequences, consistent with a mechanism for 
integration involving viral genome replication and microhomology-mediated 
recombination, which has an important role in the integration of other tumori-
genic viruses, HBV and HPV [54, 59]. Meanwhile, researchers also observed 
integrations of short EBV fragments into human chromosomes, coincident with 
episomal EBV genomes in NKTCL, and showed that 31 EBV-host integration sites 
were detected from eight NKTCL samples, and enriched in the repeat regions of 
human genome, such as SINE, LINE, and satellite [24].
However, there are still few studies on EBV integration based on WGS tech-
nology. In addition, authors only selected some potential breakpoints to perform 
PCR and Sanger sequencing for validating. For example, Xu et al. randomly 
select 12 integrations from 197 breakpoints identified from NPC and other EBV-
associated malignancies, and only 10 breakpoints were successfully validated 
[27]. As integration of EBV sequence into the host genome and the consequent 
disruption of the important host genes might represent a novel tumorigenesis 
mechanism in EBV associated malignancies, all the potential EBV integration 
breakpoints should be validated and biological function of host genes involved 
should be further conducted.
6. Summary
In conclusion, full-length EBV genomes isolated from primary NPC, EBVaGC, 
and NKTCL biopsy specimens have been successfully sequenced and the sequence 
diversity on a whole-genome level has been analyzed, although their pathogenesis 
remains to be clarified. Phylogenetic analysis has shown that all aforementioned 
NPC, GC, and NKTCL-EBV strains are type 1 EBV and close to other Asian subtypes, 
leading to the conclusion that EBV infections are more likely affected by different 
geographic regions rather than particular EBV-associated malignancies. In addi-
tion, sequence variations of EBV genes also result in amino acid epitope exchanges, 
which should have a significant impact on EBV-specific T-cell immunity. Recent data 
have provided optimization proposal for selecting EBV genome for treatment from 
individual patients or at least predominant strains prevalent in geographical regions 
instead of commonly used B95-8 genome. We acknowledge that further charac-
terizations of the molecular events would provide more information on the exact 
mechanisms underlying their pathogenic potentials and clinical significance.
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